TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Mid-term disease progression in terms of cognitive functioning
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of participants with transient ischemic attack, fatal and non-fatal ischaemic or unspecific stroke
Endpoint domain: Mortality/survival
Primary endpoint: Number of participants with fatal or non-fatal major bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency in headache days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency in migraine days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of moderate/severe headache days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Log transformed values of AUCL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Log transformed values of Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of peritoneal metastases detected
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Ventilation Heterogeneity Index (VHI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of severe radiographic vasospasm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change in Hamilton-Depression Rating Scale (SIGH-D)-17 Items
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Hamilton-Depression Rating Scale (SIGH-D)-31 Item
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Erectile Dysfunction change score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SOFA score difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of episodes of serum K ≥ 5.5 mEq/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants With Grade 3 or 4 Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Grade 5 AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With AEs Leading to Treatment Discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: radiation absorbed dose in the prostate and involved lymph nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immune and/or genetic defects predisposition to severe viral infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Muscle insulin sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Major structural defects in children
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Biliary cannulation difficulty
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Maintained an Exercise Regimen Average of 18 MET Per Week or Greater
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total Morphine Milligram Equivalents (MME) Used
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: N-balances
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of body movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microscopic hematuria (RBC's)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of serious adverse reactions
Endpoint domain: Adverse events/effects
Primary endpoint: glycosylated hemoglobin (A1C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: percent predicted forced vital capacity (FVC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change on dynamic balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change on functional performance
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change on pain intensity level
Endpoint domain: Adverse events/effects
Primary endpoint: Change on disability level
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Dizziness Handicap Inventory score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Total weight change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Tumor response rate (CR+PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change of scoliosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in body core temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skin sympathetic nerve activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Proportion of Participants Maintaining Average Haemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Changes in Senescence and Secondary Biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fluid Removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6 Item Hamilton Depression Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Positive and Negative Affect Score (PANAS) - Negative Subscale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Positive and Negative Affect Score (PANAS) - Positive Subscale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Development of Nephrogenic Systemic Fibrosis (NSF)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Known Pregnancy Outcomes
Endpoint domain: Mortality/survival
Primary endpoint: Intraocular pressure lowering
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival rate to Total Hip Prothesis
Endpoint domain: Mortality/survival
Primary endpoint: Change from baseline of peak oxygen uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Neuropsychiatric Inventory (NPI) apathy/indifference domain score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Difference in 6 min walk distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Narcotic Usage
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incidence of Acute GVHD by Day 100
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Eating Disorders Examination Questionnaire (EDEq) score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Early Stroke
Endpoint domain: Mortality/survival
Primary endpoint: Nocturnal gas exchange (PCO2 (kPa))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Minimum Joint Space Width in the Medial Compartment of the Tibiofemoral Joint
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Total Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Incidence of development of late AMD
Endpoint domain: Mortality/survival
Primary endpoint: pre-dialytic serum beta-2 microglobulin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of MAP measurement for detecting intraoperative hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: prevalence of clinical strains of Enterobacteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change (Improvement) of CAT (Italian version)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change (Improvement) of mMRC (Italian version)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change (Improvement) of R5-R20 (kPa x s x L-1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants who experienced adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change of the Physician's global assessment of the target lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of malposition of blindly placed gastric tubes
Endpoint domain: Adverse events/effects
Primary endpoint: adherence to medical care
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: safer sexual behavior
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Improved Skin Moisturization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Clinically-significant prostate cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change From Baseline in Acceptability of Implementation Measure (AIM-Imp) Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change From Baseline in Implementation Appropriateness Measure (IAM-Imp) Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change From Baseline in Feasibility of Implementation Measure (FIM-Imp) Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Urinary Calcium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: cumulative BOS-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of Symptomatic Intracranial Hemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change From Baseline in Average Eye Mean Diurnal Intraocular Pressure (IOP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Cardiovascular mortality or hospitalisation due to congestive heart failure
Endpoint domain: Mortality/survival
Primary endpoint: Rate of Prevention of Retrograde Stone or Stone Fragment Migration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Oswestry Disability Index success
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: No serious AE classified as implant or implant/surgical procedure associated
Endpoint domain: Adverse events/effects
Primary endpoint: Correlatability between imaging morphology and histological characteristics of breast lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Predictive value of UIA wall enhancement for UIA growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neurocognitive deficit
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: direction core muscle ratio (DCMR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: core muscle state ratio (CMSR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of patients with elevated D-dimer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percent Change in Hamilton Depression Rating Scale (HAMD-17)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Macula diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients achieving ASAS 40 response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reason for tooth extraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Menopause symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Participants With Solicited Local Reactions Within 7 Days Following Each Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Solicited General Reactions Within 7 Days Following Each Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Unsolicited Adverse Events Within 28 Days Following Any Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Grade 2 or Higher Hematological and Biochemical Laboratory Abnormalities From Day 8 to Day 113
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Assessment of Parkinson's disease domains
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Retinal function assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eye movement assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: APACHE II SCORE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Clinician-Administered PTSD Scale (CAPS) at 8 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Posttraumatic Diagnostic Scale (PDS) at 8 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Needs of family cancer caregivers
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Function of right heart
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change score in SA-SIP 30
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage of Subjects With Seropositivity Against At Least 1, 2, 3, or 4 Parental Dengue Virus Serotypes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Children's Hand-Use Experience Questionnaire (CHEQ)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Remineralisation of white spot lesions (WSLs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participants' perception of the appearance of WSLs
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from baseline knee OA symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from baseline functional strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Residual enzymatic activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: concentration of inflammatory markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Child Height-for-age Z-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Child Weight-for-Height Z-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean PAI-1 Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Follicle stimulating hormone (mIU/MI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Leutinizing Hormone (mIU/MI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Sex hormone binding globulin (mg/dL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Serum Prolactin (ng/ml)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change of expression of P-selectin and fibrinogen receptor activation on platelets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change of in vitro bleeding time using the Platelet Function Analyzer (PFA-100)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of coagulation marker assessed as fibrinogen levels in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Biomechanical responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Sleep Quality - Pittsburgh Sleep Quality Index (PSQI)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Daytime Sleepiness - Epworth Sleepiness Scale
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Post-Concussive Symptoms (Rivermead Post-Concussion Symptoms Questionnaire)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Listening Effort
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: 6-month Progression-free Survival (PFS) Proportion
Endpoint domain: Mortality/survival
Primary endpoint: Cadaverine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Choline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hypoxanthine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Inosine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Isoleucine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Leucine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Frequency of unsolicited adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of medically-attended AEs, adverse events of special interest (AESI), and serious adverse events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of clinical laboratory adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in ground reaction force
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in ground reaction force loading rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in knee flexion excursion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in spatiotemporal gait symmetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: assess skill level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Decisional Conflict
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of Responders After 1 Year of Follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of serious and non-serious adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Tolerated Dose (MTD) / Recommended Phase 2 Dose (RP2D)
Endpoint domain: Adverse events/effects
Primary endpoint: Neonatal mortality from post enrolment to 28 days
Endpoint domain: Mortality/survival
Primary endpoint: Early infant mortality from post enrolment to 6 months of age
Endpoint domain: Mortality/survival
Primary endpoint: Device-related peri-procedural complications
Endpoint domain: Adverse events/effects
Primary endpoint: Symptomatic Intracranial Cerebral Hemorrhage (SICH)
Endpoint domain: Adverse events/effects
Primary endpoint: Embolization to a previously uninvolved territory
Endpoint domain: Adverse events/effects
Primary endpoint: steady-state pharmacokinetics of paliperidone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of HIV-1 antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Rate of early stage invasive cancer detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Interval or advanced breast cancer rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: 3-year rate of 2nd breast cancer events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in left ventricle ejection fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: thoracoabdominal motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal tolerated dose (MTD) of zileuton
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in visual characterization of PET scans
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change standardized uptake values of PET scans
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decision Regret Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pure tone audiometric threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discomfort with intranasal midazolam administration
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Institutional delivery rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Autism: Parenting Questionnaire (APQ)
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: serum level of cardiac troponin T (cTnT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of sleeping through the night
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Negative Emotions
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Perception of Health
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: relapse due to reinfection
Endpoint domain: Adverse events/effects